BMO Capital took its Sabra Health Care REIT [SBRA] rating to the equivalent of Market Perform from Underperform, and the price target to $19.0, in a research note dated 2021-01-08. That figure represents around a 11.6% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with JMP Securities’s analysts upgrading the shares from “a Mkt perform” rating to “a Mkt outperform” rating in a research note to investors issued in early December. In addition, there was an upgrade from Scotiabank on June 23, 2020. The rater changed SBRA from “a Sector underperform” to “a Sector perform”.
Is Sabra Health Care REIT Inc. [NASDAQ:SBRA] a Good Buy Right Now?
It should be noted that SBRA technical indicators for short, intermediate as well as long term progress have placed an overall average of 80% as Buy. The average signal changed from 88% Buy in the last week and compares with 100% Buy in the past month. Data from Sabra Health Care REIT Inc.’s Trend Spotter indicated that the signals were Falling. The stock current average is 1.57 million shares in the past 20 days and the short term average signal indicates a 50% Buy. In the last 50 days, the average trading volume was 1.89 million shares while the medium term average advocated for 100% Buy. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 1.65 million shares.
SBRA Price Performance
On Wall Street, Sabra Health Care REIT Inc. [NASDAQ:SBRA] finished Thursday’s session down -3.10% at $17.02. The stock went up to $17.52 at the same session while its lowest single day price was $16.805. In the last five days, it saw a fall of about -3.07%, Sabra Health Care REIT Inc. shares dropped by almost -1.99% since the beginning of the year. However, the share price has dropped to as low as -24.48% below its one year high. On 01/06/21, the company shares recorded $17.81, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/07/21, the same year at $16.81. The company’s shares have declined by -19.84% in the past year. The 50-day SMA achieved is $16.62 while the 200-day SMA is $14.57. Volume dropped to 1.47 million from 2.11 million in the previous session.
Sabra Health Care REIT Inc. [SBRA] Valuation Measures
Notably, Sabra Health Care REIT Inc. [SBRA] stock cannot be classified as a good candidate in the listing of underestimated low-priced REIT – Healthcare Facilities companies to purchase soonest possible with the prevailing 12-month PE ratio of 24.64. The measure means the stock is exchanging at a premium as compared to the 19.03x trailing earnings of the industry. It can be helpful for investors to consider historical price-sales ratio, more specifically, a 5.91 PS value ratio is reported for the last one year of reported earnings. That is lower than the industry average of 7.40 which means SBRA serve an unattractive investment opportunity compared to its competitors.
SBRA Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 16.71 level, and in case of violation of this particular level, it will cause more drop to 16.40 level. On the upper level, 17.83 is still the key resistance. The stock may increase to the subsequent resistance at 17.43. The Relative Strength Index (RSI) pinned on the 14-day chart is 47.15, implying a neutral technical stance while the MACD stands at -0.21, meaning price will decrease in the next trading period. Percent R indicator moved to 81.28%, implying bearish price movement. Stochastic %K at 33.32% suggest selling the stock.
What is the short interest in Sabra Health Care REIT Inc.?
Short interest in the Sabra Health Care REIT Inc. stock has plunged, decreasing by -0.31 million shares to total 7.14 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 6.83 million, data from Yahoo Finance shows. The increase of 4.34% suggests the stock saw some increased bearish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 4.89% of the overall float for the stock.
Sabra Health Care REIT Inc.’s Biggest Shareholders: Who Owns Sabra Health Care REIT Inc. [SBRA]?
Filings by The Vanguard Group, Inc. showed that the firm now holds a total of 31,087,560 shares or roughly 15.02% of the outstanding SBRA shares. This means their shares have reduced by -1,165,630 from the 31,087,560 the investor reportedly held in its prior 13-F filing. With the conclusion of the sale, BlackRock Fund Advisors updated stake is worth $385,576,677. Details in the latest 13F filings reveal that Principal Global Investors LLC acquired their 0.71% stake valued at $162,234,064 while SSgA Funds Management, Inc. cut theirs at $140,739,216. During the last quarter, Principal Global Investors LLC raised 69,883 of its shares in Sabra Health Care REIT Inc. while SSgA Funds Management, Inc. sold -710,076 shares. The Mellon Investments Corp.’s holdings currently number 6,171,894 shares at $105045635.88. According to the firm’s last 13F report, Long Pond Capital LP shares in the company at filing stood at 6,150,349 shares, roughly $101,357,752.
SBRA Earnings Forecast For The Current Quarter
Sabra Health Care REIT Inc. [SBRA] is expected to report weak earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $151.52M and an earnings per share of $0.16 for Dec 2020. Looking further ahead, the company is expected to report revenue of $152.03M at an EPS of $0.16 for Mar 2021. The estimates represent downside of 2.90% and 7.99% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
SBRA Earnings Estimates For The Current Year
For the financial year, Sabra Health Care REIT Inc. [NASDAQ:SBRA] is expected to bring in revenue of $595.36M. The returns are nearly $10.22 million higher than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at 0.66, higher than that of FY19 by $0.29. Estimates put this year’s earnings growth at 78.40%, 9.10% for the next, and at an annual 6.00% over the next 5-year period. As for sales, forecasts are for an increase of 1.70% in the current fiscal year and a further 2.90% over the following year.